ScholarIQanswers from OpenAlex
Clinica Universidad de Navarra
InstitutionResearch output, impact & collaborations
Clinica Universidad de Navarra is a institution indexed in ScholarIQ from OpenAlex.
What is known about Clinica Universidad de Navarra?
ScholarIQrecord summary
Clinica Universidad de Navarra is a research organisation in Pamplona, ES. OpenAlex records 27,157 works and 1,135,580 citations for it. 6,602 researchers list it as their most recent affiliation.
How many works does Clinica Universidad de Navarra have?
ScholarIQindexed works
Clinica Universidad de Navarra has 27,157 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
How many citations does Clinica Universidad de Navarra have?
ScholarIQcitation count
Clinica Universidad de Navarra has 1,135,580 citations in the OpenAlex counts ScholarIQ stores.
How many researchers are at Clinica Universidad de Navarra?
ScholarIQresearcher count
Clinica Universidad de Navarra has 6,602 researchers in the ScholarIQ index.
What is the average h-index at Clinica Universidad de Navarra?
ScholarIQavg h-index
Clinica Universidad de Navarra has an average h-index of 69.4 in OpenAlex.
What is the ROR of Clinica Universidad de Navarra?
ScholarIQror
The ROR for Clinica Universidad de Navarra is on the source record.
What is the OpenAlex record for Clinica Universidad de Navarra?
ScholarIQopenalex
The OpenAlex for Clinica Universidad de Navarra is on the source record.
Who are the most-cited researchers behind Clinica Universidad de Navarra?
ScholarIQtop researchers by citations
What are the most-cited papers on Clinica Universidad de Navarra?
ScholarIQmost cited works
Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial
Roy S. Herbst, Paul Baas, Dong‐Wan Kim, Enriqueta Felip, José Luis Perez‐Gracia, Ji‐Youn Han, Julian R. Molina, Joo-Hang Kim, Catherine Dubos Arvis, Myung‐Ju Ahn, Margarita Majem, Mary J. Fidler, Gilberto de Castro, Marcelo Garrido, Gregory M. Lubiniecki, Yue Shentu, Ellie Im, Marisa Dolled‐Filhart, Edward B. Garon
Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial
Jonathan E. Rosenberg, Jean Hoffman‐Censits, Tom Powles, Michiel S. van der Heijden, Arjun Vasant Balar, Andrea Necchi, Nancy A. Dawson, Peter H. O’Donnell, Ani Sarkis Balmanoukian, Yohann Loriot, Sandy Srinivas, Margitta Retz, Petros Grivas, Richard W. Joseph, Matthew D. Galsky, Mark T. Fleming, Daniel P. Petrylak, José Luis Perez‐Gracia, Howard A. Burris, Daniel Castellano, Christina Canil, Joaquim Bellmunt, Dean F. Bajorin, Dorothee Nickles, Richard Bourgon, Garrett M. Frampton, Na Cui, Sanjeev Mariathasan, Oyewale O. Abidoye, Gregg Fine, Robert Dreicer
A microRNA DNA methylation signature for human cancer metastasis
Amaia Lujambio, George A. Calin, Alberto Villanueva, Santiago Ropero, Montse Sánchez‐Céspedes, David Blanco, Luis M. Montuenga, Simona Rossi, Milena S. Nicoloso, William J. Faller, William M. Gallagher, Suzanne A. Eccles, Carlo M. Croce, Manel Esteller
Impaired HLA Class I Antigen Processing and Presentation as a Mechanism of Acquired Resistance to Immune Checkpoint Inhibitors in Lung Cancer
Scott Gettinger, Jungmin Choi, Katherine Hastings, Anna Truini, Ila Datar, Ryan Sowell, Anna Wurtz, Weilai Dong, Guoping Cai, Mary Ann Melnick, Victor Y. Du, Joseph Schlessinger, Sarah B. Goldberg, Anne C. Chiang, Miguel F. Sanmamed, Ignacio Melero, Jackeline Agorreta, Luis M. Montuenga, Richard P. Lifton, Soldano Ferrone, Paula Kavathas, David L. Rimm, Susan M. Kaech, Kurt A. Schalper, Roy S. Herbst, Katerina Politi
Biomarkers in Lung Cancer Screening: Achievements, Promises, and Challenges
Luis Seijó, Nir Peled, Daniel Ajona, Mattia Boeri, John K. Field, Gabriella Sozzi, Rubén Pı́o, Javier J. Zulueta, Avrum Spira, Pierre P. Massion, Peter J. Mazzone, Luis M. Montuenga
How much of the research on Clinica Universidad de Navarra is open access?
ScholarIQopen access share
58%OPEN ACCESS